Companies Dominating the Human Combinatorial Antibody Libraries (HuCAL) Market
- MorphoSys A.G.
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bio-Rad
- Adimab, LLC
- Taurus Biosciences
- ImmunoGen
- BioInvent International AB
- Creative Biolabs
- YUMAB GmbH
- Hoffman-La Roche Ltd.
- Creative Biolabs
Browse Key Market Insights with Data Illustration:
In the News
February 5, 2024: MorphoSys AG, declared that it entered into a Business Combination Agreement with Novartis data42 AG and Novartis AG dependent on Novartis' intention to deliver a voluntary public takeover deal for all of MorphoSys' superior common shares in exchange for money of € 68.00 per share.
January 30, 2024: MorphoSys AG reported preliminary Monjuvi® U.S. net material sales and gross margin for Monjuvi U.S. net product sales for the complete year of 2023 and given its 2024 financial assistance. In this environment, MorphoSys limits its financial liability from the cooperation with its partner Incyte and credits finance income consequently.
